Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian Ball

Showing results (31-40 of 52) with videos related to

Pageof 6
Sort By:
Leukemia|February 20, 2024
Hypomethylating agents plus venetoclax compared with intensive induction chemotherapy regimens in molecularly defined secondary AMLShai Shimony, Jan Philipp Bewersdorf, Rory M Shallis, et al.
Cancers|December 17, 2024
Combined Cytokine Blockade Therapy (CCBT) Using Basiliximab and Infliximab for Treatment of Steroid-Refractory Graft-Versus-Host Disease (SR-GvHD)Hoda Pourhassan, Tina Nguyen, Dongyun Yang, et al.
Leukemia Research|August 29, 2024
Impact of spliceosome mutation on outcomes of myelodysplastic syndrome and chronic myelomonocytic leukemia patients undergoing allogeneic hematopoietic cell transplantationAmrita Desai, Yazeed Samara, Dongyun Yang, et al.
Bone Marrow Transplantation|August 15, 2024
Comparing transplant outcomes in ALL patients after myeloablative conditioning in mismatch-related or unrelated donor settingsSalman Otoukesh, Dongyun Yang, Sally Mokhtari, et al.
Bone Marrow Transplantation|November 18, 2025
Long-term survival outcomes of allo-HCT in AML with fludarabine/melphalan conditioning and tacrolimus/sirolimus GVHD prophylaxisAmandeep Salhotra, Dongyun Yang, Monzr M Al Malki, et al.
Leukemia & Lymphoma|August 3, 2023
<i>WT1</i>-mutated acute myeloid leukemia is sensitive to fludarabine-based chemotherapy and conditioning regimensAhmed Aribi, Amandeep Salhotra, Michelle Afkhami, et al.
Transplantation and Cellular Therapy|August 9, 2024
Total Body Irradiation and Fludarabine with Post-Transplantation Cyclophosphamide for Mismatched Related or Unrelated Donor Hematopoietic Cell TransplantationShukaib Arslan, Amrita Desai, Dongyun Yang, et al.
Bone Marrow Transplantation|December 18, 2024
Fludarabine melphalan reduced intensity conditioning vs radiation-based myeloablative conditioning in patients undergoing allogeneic transplantation for acute myeloid leukemia with measurable residual diseaseAmanda Blackmon, Michelle Afkhami, Dongyun Yang, et al.
The Lancet. Haematology|May 18, 2026
Total marrow and lymphoid irradiation in combination with cyclophosphamide and etoposide before haematopoietic cell transplantation for relapsed or refractory acute leukaemia: a single-centre, open-label, phase 2 trialAnthony Stein, Yan Wang, Monzr M Al Malki, et al.
American Journal of Hematology|May 16, 2024
Combination therapy with hypomethylating agents and venetoclax versus intensive induction chemotherapy in IDH1- or IDH2-mutant newly diagnosed acute myeloid leukemia-A multicenter cohort studyJan Philipp Bewersdorf, Shai Shimony, Rory M Shallis, et al.
Pageof 6

Showing results (31-40 of 52) with videos related to

Sort By:
Pageof 6
Leukemia|February 20, 2024
Hypomethylating agents plus venetoclax compared with intensive induction chemotherapy regimens in molecularly defined secondary AMLShai Shimony, Jan Philipp Bewersdorf, Rory M Shallis, et al.
Cancers|December 17, 2024
Combined Cytokine Blockade Therapy (CCBT) Using Basiliximab and Infliximab for Treatment of Steroid-Refractory Graft-Versus-Host Disease (SR-GvHD)Hoda Pourhassan, Tina Nguyen, Dongyun Yang, et al.
Leukemia Research|August 29, 2024
Impact of spliceosome mutation on outcomes of myelodysplastic syndrome and chronic myelomonocytic leukemia patients undergoing allogeneic hematopoietic cell transplantationAmrita Desai, Yazeed Samara, Dongyun Yang, et al.
Bone Marrow Transplantation|August 15, 2024
Comparing transplant outcomes in ALL patients after myeloablative conditioning in mismatch-related or unrelated donor settingsSalman Otoukesh, Dongyun Yang, Sally Mokhtari, et al.
Bone Marrow Transplantation|November 18, 2025
Long-term survival outcomes of allo-HCT in AML with fludarabine/melphalan conditioning and tacrolimus/sirolimus GVHD prophylaxisAmandeep Salhotra, Dongyun Yang, Monzr M Al Malki, et al.
Leukemia & Lymphoma|August 3, 2023
<i>WT1</i>-mutated acute myeloid leukemia is sensitive to fludarabine-based chemotherapy and conditioning regimensAhmed Aribi, Amandeep Salhotra, Michelle Afkhami, et al.
Transplantation and Cellular Therapy|August 9, 2024
Total Body Irradiation and Fludarabine with Post-Transplantation Cyclophosphamide for Mismatched Related or Unrelated Donor Hematopoietic Cell TransplantationShukaib Arslan, Amrita Desai, Dongyun Yang, et al.
Bone Marrow Transplantation|December 18, 2024
Fludarabine melphalan reduced intensity conditioning vs radiation-based myeloablative conditioning in patients undergoing allogeneic transplantation for acute myeloid leukemia with measurable residual diseaseAmanda Blackmon, Michelle Afkhami, Dongyun Yang, et al.
The Lancet. Haematology|May 18, 2026
Total marrow and lymphoid irradiation in combination with cyclophosphamide and etoposide before haematopoietic cell transplantation for relapsed or refractory acute leukaemia: a single-centre, open-label, phase 2 trialAnthony Stein, Yan Wang, Monzr M Al Malki, et al.
American Journal of Hematology|May 16, 2024
Combination therapy with hypomethylating agents and venetoclax versus intensive induction chemotherapy in IDH1- or IDH2-mutant newly diagnosed acute myeloid leukemia-A multicenter cohort studyJan Philipp Bewersdorf, Shai Shimony, Rory M Shallis, et al.
Pageof 6